Treatment of anemia in heart failure: Potential risks and benefits of intravenous iron therapy in cardiovascular disease

Cardiology in Review

Volumn 18, Issue 5, 2010, Pages 240-250

  Jelani, Qurat Ul Ain ^a   Katz, Stuart D ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE PROTOPORPHYRIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; NITRIC OXIDE; TRANSFERRIN;

BLOOD DONOR; BONE MARROW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; CHRONIC KIDNEY DISEASE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; FUNCTIONAL STATUS; HEART FAILURE; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; MITOCHONDRIAL RESPIRATION; NEUROTOXICITY; PANCREAS DISEASE; PHLEBOTOMY; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; SKELETAL MUSCLE; TRANSFERRIN BLOOD LEVEL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANEMIA, IRON-DEFICIENCY; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; RISK FACTORS; TRACE ELEMENTS;

EID: 77955830245     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181e71150     Document Type: Review

References (124)

1. Failla ML. Trace elements and host defense: recent advances and continuing challenges. JNutr. 2003;133:1443S-1447S.
2. Gordeuk VR, Bacon BR, Brittenham GM. Iron overload: causes and consequences. Annu Rev Nutr. 1987;7:485-508.
3. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001;131:568S-579S.
4. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program. 2003:40-61.
5. Beutler E. Cell biology. "Pumping" iron: the proteins. Science. 2004;306: 2051-2053.
6. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
7. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788.
8. Swinkels DW, Janssen MC, Bergmans J, et al. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem. 2006;52: 950-968.
9. Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381-1387.
10. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008; 15:169-175.
11. Collins JF, Wessling-Resnick M, Knutson MD. Hepcidin regulation of iron transport. J Nutr. 2008;138:2284-2288.
12. McCord JM. Iron, free radicals, and oxidative injury. J Nutr. 2004;134: 3171S-3172S.
13. Meyron-Holtz EG, Ghosh MC, Rouault TA. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science. 2004;306: 2087-2090.
14. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002; 32(suppl 1):50-54.
15. Richardson DR, Ponka P. The molecular mechanisms ofthe metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331:1-40.
16. Ponka P. Cellular iron metabolism. Kidney Int Suppl. 1999;69:S2-S11.
17. Ali A, Zhang Q, Dai J, et al. Calcein as a fluorescent iron chemosensor for the determination of low molecular weight iron in biological fluids. Biomet-als. 2003;16:285-293.
18. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci. 2000;23:185-192.
19. Brittenham GM, Weiss G, Brissot P, et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Hematol Am Soc Hematol Educ Program. 2000:39-50.
20. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002;282:G403-G414.
21. Andrews NC. Disorders of iron metabolism. NEnglJMed. 1999;341:1986-1995.
22. Beard J. Iron status of free-living elderly individuals. Am J Clin Nutr. 2001;73:503-504.
23. Barron BA, Hoyer JD, Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol. 2001;80:166-169.
24. Herbert V. Anemias. In: Paige DM, ed. Clinical Nutrition. St. Louis, CV: Mosby; 1988:593.
25. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
26. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-628.
27. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). JAm Coll Cardiol. 2003;41:1933-1939.
28. Kosiborod M, Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-119.
29. Tanner H, Moschovitis G, Kuster GM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002;86:115-121.
30. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart. 2002;87: 377-378.
31. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
32. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol. 2003;91:888-891.
33. Szachniewicz J, Petruk-Kowalczyk J, Majda J, et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. 2003;90:303-308.
34. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
35. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4:681-686.
36. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16:87-96.
37. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38:443-452.
38. Torre-Amione G, Bozkurt B, Deswal A, et al. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol. 1999;14:206-210.
39. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol. 2002;85:161-171.
40. Kalra PR, Anagnostopoulos C, Bolger AP, et al. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol. 2002; 39:1901-1908.
41. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-362.
42. Iversen PO, Woldbaek PR, Tonnessen T, et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166-R172.
43. Gossmann J, Burkhardt R, Harder S, et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int. 2001;60:83-86.
44. Pratt MC, Lewis-Barned NJ, Walker RJ, et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol. 1992;34:363-365.
45. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000;2:393-398.
46. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. JAm Coll Cardiol. 2005;45:391-399.
47. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485-2489.
48. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
49. Westenbrink BD, Voors AA, van Veldhuisen DJ. Is anemia in chronic heart failure caused by iron deficiency? J Am Coll Cardiol. 2007;49:2301-2302; author reply 2302.
50. Berry C, Norrie J, Hogg K, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J. 2006;151:1313-1321.
51. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-16.
52. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323: 236-241.
53. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-2461.
54. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
55. Ludwiczek S, Aigner E, Theurl I, et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003;101:4148-4154.
56. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
57. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227.
58. Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. JAm Coll Cardiol. 2007;50:1657-1665.
59. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51: 103-112.
60. Usmanov RI, Zueva EB, Silverberg DS, et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21:236-242.
61. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. NEngl J Med. 2009;361:2436-2448.
62. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
63. Katz SD, Zheng H. Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. J Nucl Cardiol. 2002;9:215-225.
64. Rouault TA, Klausner RD. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem Sci. 1996;21:174-177.
65. Haas JD, Brownlie TT. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131: 676S-688S; discussion 688S-690S.
66. Finch CA, Miller LR, Inamdar AR, et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest. 1976;58:447-453.
67. Davies KJ, Maguire JJ, Brooks GA, et al. Muscle mitochondrial bioener-getics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol. 1982;242:E418-E427.
68. Davies KJ, Donovan CM, Refino CJ, et al. Distinguishing effects of anemia and muscle iron deficiency on exercise bioenergetics in the rat. Am J Physiol. 1984;246:E535-E543
69. Willis WT, Gohil K, Brooks GA, et al. Iron deficiency: improved exercise performance within 15 hours of iron treatment in rats. J Nutr. 1990;120: 909-916.
70. Perkkio MV, Jansson LT, Henderson S, et al. Work performance in the iron-deficient rat: improved endurance with exercise training. Am J Physiol. 1985;249:E306-E311.
71. McLane JA, Fell RD, McKay RH, et al. Physiological and biochemical effects of iron deficiency on rat skeletal muscle. Am J Physiol. 1981;241: C47-C54.
72. Brutsaert TD, Hernandez-Cordero S, Rivera J, et al. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr. 2003;77:441-448.
73. Brownlie T IV, Utermohlen V, Hinton PS, et al. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr. 2002;75:734-742.
74. Brownlie Tt, Utermohlen V, Hinton PS, et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437-443.
75. Hinton PS, Giordano C, Brownlie T, et al. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol. 2000;88:1103-1111.
76. McClung JP, Karl JP, Cable SJ, et al. Randomized, double-blind, placebo-controlled trial of iron supplementation in female soldiers during military training: effects on iron status, physical performance, and mood. Am J Clin Nutr. 2009;90:124-131.
77. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem. 2008;15:2157-2172.
78. Sullivan JL. Is stored iron safe? J Lab Clin Med. 2004;144:280-284.
79. Lee TS, Shiao MS, Pan CC, et al. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999;99:1222-1229.
80. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci. 2002;967:342-351.
81. Lee HT, Chiu LL, Lee TS, et al. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. JBiomedSci. 2003;10:510-517.
82. Patt A, Horesh IR, Berger EM, et al. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. JPediatr Surg. 1990; 25:224-227; discussion 227-228.
83. Ponraj D, Makjanic J, Thong PS, et al. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBSLett. 1999;459:218-222.
84. van Jaarsveld H, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis. 2002;161:395-402.
85. Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004;51:471-480.
86. McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol. 1998;35:5-12.
87. Gey KF. Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Br Med Bull. 1993;49:679-699.
88. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol. 1997;7:62-68.
89. Wardman P, Candeias LP. Fenton chemistry: an introduction. Radiat Res. 1996;145:523-531.
90. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation .2003;107:1053-1058.
91. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations ofvasomotor tone. J Clin Invest. 1996;97:1916-1923.
92. Pagano PJ, Clark JK, Cifuentes-Pagano ME, et al. Localization of a consti-tutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA. 1997;94:14483-14488.
93. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am JHypertens. 2001;14:44S-54S.
94. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001;107:1209-1210.
95. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol. 2004;76:760-781.
96. Yu L, Zhen L, Dinauer MC. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem. 1997;272:27288-27294.
97. Taille C, El-Benna J, Lanone S, et al. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem. 2004;279: 28681-28688.
98. Li L, Frei B. Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol. 2009;29: 732-738.
99. Marx JJ, Kartikasari AE, Georgiou NA. Can iron chelators influence the progression of atherosclerosis? Hemoglobin. 2008;32:123-134.
100. Minqin R, Watt F, Huat BT, et al. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic Biol Med. 2003;34:746-752.
101. Thong PS, Selley M, Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol (Noisy-le-grand). 1996;42:103-110.
102. Minqin R, Rajendran R, Pan N, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med. 2005;38: 1206-1211.
103. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286(pt 3):901-905.
104. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294.
105. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J. 2003;145:190-194.
106. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49: 476-488.
107. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85: 447-452.
108. Hulley S, Grady D, Bush T, et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
109. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
110. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-811.
111. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation. 1999;99:852-854.
112. Finch CA, Cook JD, Labbe RF, et al. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood. 1977;50:441-447.
113. Milman N, Kirchhoff M. The influence of blood donation on iron stores assessed by serum ferritin and hemoglobin in a population survey of 1359 Danish women. Ann Hematol. 1991;63:27-32.
114. Tuomainen TP, Salonen R, Nyyssonen K, et al. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314:793-794.
115. Meyers DG, Strickland D, Maloley PA, et al. Possible association of a reduction in cardiovascular events with blood donation. Heart. 1997;78: 188-193.
116. Ascherio A, Rimm EB, Giovannucci E, et al. Blood donations and risk of coronary heart disease in men. Circulation. 2001;103:52-57.
117. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42:1135-1139.
118. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297:603-610.
119. Zheng H, Cable R, Spencer B, et al. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005;25:1577-1583.
120. Zheng H, Dimayuga C, Hudaihed A, et al. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterio-scler Thromb Vasc Biol. 2002;22:E15-E18.
121. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804.
122. Zheng H, Huang X, Zhang Q, et al. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int. 2006;69: 679-684.
123. Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002;32(suppl 1):9-16.
124. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584-590.